Global Phase III trial of enzalutamide in progressive, high-risk prostate cancer

According to a joint media release from Medivation and Astellas earlier today, the companies will soon be initiating an important and major new trial of enzalutamide in men with progressive prostate cancer after first-line therapy. … READ MORE …

Long-term impact on workplace status after radical prostatectomy

A recent Norwegian study has concluded that pre-surgical counseling of men electing treatment for prostate cancer by radical prostatectomy needs to include advice about risk for the possibility of post-surgical issues that may affect work status and their working life 3 years after their surgery. … READ MORE …

Second-line therapy for progressive, high-risk prostate cancer: time for a STAMPEDE-like trial?

Let’s say you are 58 years of age, in apparently excellent health for your age, when you get diagnosed with high-risk prostate cancer, based on a Gleason score of 4 + 4 = 8, a PSA level of 3.7, and a clinical stage of T1c, with 4/12 biopsy cores positive for cancer. … READ MORE …

One more reason to cut out the cigarettes

Surgeons already don’t like to operate on smokers. They don’t do as well during and after surgery as non-smokers, not least because smokers can have problems with anesthesia. Now come data suggesting that smoking during radiation therapy is a pretty lousy idea too. … READ MORE …

Heart-related mortality in men on ADT: a current perspective

A newly published study in BJU International suggests (unsurprisingly) that androgen deprivation therapy (ADT) is associated with an increased risk of death among men with such cardiovascular conditions as congestive heart failure or prior heart attacks. … READ MORE …

The PrKT03 trial of radiation + immunotherapy for localized prostate cancer

Back in September 2011, a company called Advantagene initiated a randomized, placebo-controlled, Phase III clinical trial (the PrKT01 trial) of an immunotherapeutic agent known as AdV-tk, together with with standard external beam radiation therapy, in highly-defined patients with newly diagnosed, localized prostate cancer. … READ MORE …

Cancer drugs that don’t extend survival

An article by John Fauber in this Sunday’s issue of the Milwaukee Journal-Sentinel has been receiving a lot of attention in the oncology news over the past 48 hours. The title of this article is “FDA approves cancer drugs without proof they’re extending lives.” … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,157 other followers